NM-2201 is going approximately as a complete agonist with a coupling proclivity of zero.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors. It’s been connected to genuine unfriendly occasions in customers.
NM-2201 become related to an prevalence in December 2015 wherein 25-30 individuals in Ocala, FL have been taken to clinical clinics next to encountering seizures.
NM-2201 is bought for studies purposes simply and isn’t be used for some different purposes, inclusive of, but no longer restrained to, in vivo demonstrative purposes, in nourishments, in medicines, in therapeutic devices, and additionally beautifying dealers for humans or potentially creatures.
NM-2201 is an indole-based totally engineered cannabinoid that seemingly has similar houses to the firmly related 5F-PB-22 and NNE1, which are each full agonists and unselectively tie to CB₁ and CB₂ receptors with low nanomolar proclivity . NM-2201 with a deliberate or IUPAC call of 1-(five-Fluoro-pentyl)- 1H-indole-3–carboxylic corrosive naphthalen-1-yl ester has a synthetic recipe of C24H22FNO2 and a precise mass of 375.16. research on NM-2201 is still earlier than all else arranged and insufficient facts is out there to illustrate its residences. Be that as it may, it’s far the easy of AM-2201 importance the qualities are similar.
NM-2201 (otherwise referred to as CBL-2201) is an indole-primarily based manufactured cannabinoid that has similar houses to it’s nearby family 5F-PB-22 and NNE1, that are both full agonists and unselectively tie to CB1 and CB2 receptors with low nanomolar partiality.